8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 2, 2026·SEC
uniQure N.V.(QURE)Earnings, Financials & Key Ratios
QURE•NASDAQ
Price updated Jun 19, 2026
AboutuniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Show more
- Revenue$16M-40.6%
- EBITDA-$173M-0.8%
- Net Income-$199M+16.9%
- EPS (Diluted)-3.46+29.7%
- Gross Margin89.53%+176.1%
- EBITDA Margin-1075.09%-69.9%
- Operating Margin-1166.77%-71.7%
- Net Margin-1236%-39.9%
- ROE-207.1%+13.2%
QURE Key Insights
uniQure N.V. (QURE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗High debt to equity ratio of 2.7x
- ✗Negative free cash flow
- ✗Sales declining 15.6% over 5 years
- ✗Shares diluted 18.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 13.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when QURE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
QURE Price & Volume
uniQure N.V. (QURE) stock price & volume — 10-year historical chart
Loading chart...
QURE Growth Metrics
uniQure N.V. (QURE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years4.56%
5 Years-15.57%
3 Years-46.73%
TTM-10.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM4%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM20.05%
Return on Capital
10 Years-24.83%
5 Years-12.46%
3 Years-33.03%
Last Year-29.38%
QURE Recent Earnings
uniQure N.V. (QURE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.85+3.4%
$0.88
Rev
$4M-31.6%
$5M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.56+39.8%
$0.93
Rev
$6M+4.5%
$5M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$1.38-62.4%
$0.85
Rev
$4M-23.6%
$5M
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.69+22.5%
$0.89
Rev
$5M+13.7%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.85vs $0.88+3.4% | $4Mvs $5M-31.6% |
| Q2 2026 | Mar 2, 2026 | $0.56vs $0.93+39.8% | $6Mvs $5M+4.5% |
| Q4 2025 | Nov 10, 2025 | $1.38vs $0.85-62.4% | $4Mvs $5M-23.6% |
| Q3 2025 | Jul 29, 2025 | $0.69vs $0.89+22.5% | $5Mvs $5M+13.7% |
Based on last 12 quarters of dataView full earnings history →
QURE Peer Comparison
uniQure N.V. (QURE) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare QURE vs Peers
uniQure N.V. (QURE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
QURE Income Statement
uniQure N.V. (QURE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.11M | 11.28M | 7.28M | 37.51M | 524M | 106.48M | 15.84M | 27.12M | 16.1M | 18.09M |
Revenue Growth % | -47.78% | -13.91% | -35.48% | 415.23% | 1296.82% | -79.68% | -85.12% | 71.17% | -40.64% | -10.44% |
Cost of Goods Sold | 67.41M | 73.06M | 0 | 122.4M | 24.98M | 3.34M | 13.63M | 18.33M | 1.69M | 4.68M |
COGS % of Revenue | 514.3% | 647.47% | - | 326.28% | 4.77% | 3.14% | 86.02% | 67.58% | 10.47% | - |
Gross Profit | -54.3M▲ 0% | -61.78M▼ 13.8% | 7.28M▲ 111.8% | -84.89M▼ 1265.9% | 499.03M▲ 687.9% | 103.14M▼ 79.3% | 2.21M▼ 97.9% | 8.79M▲ 296.9% | 14.41M▲ 63.9% | 13.41M▲ 0% |
Gross Margin % | -414.3% | -547.47% | 100% | -226.28% | 95.23% | 96.86% | 13.98% | 32.42% | 89.53% | 74.14% |
Gross Profit Growth % | -14.1% | -13.76% | 111.79% | -1265.86% | 687.88% | -79.33% | -97.85% | 296.93% | 63.92% | - |
Operating Expenses | 85.06M | 99.52M | 128.42M | 40.54M | 188.41M | 246.3M | 285.09M | 193.09M | 202.24M | 204.75M |
OpEx % of Revenue | 649% | 881.92% | 1763.78% | 108.07% | 35.96% | 231.3% | 1799.44% | 712% | 1256.3% | - |
Selling, General & Admin | 25.04M | 25.3M | 33.54M | 42.58M | 56.29M | 54.7M | 73.08M | 50.68M | 65.34M | 71.65M |
SG&A % of Revenue | 191.03% | 224.26% | 460.71% | 113.5% | 10.74% | 51.37% | 461.27% | 186.89% | 405.87% | - |
Research & Development | 72.38M | 74.81M | 94.74M | 122.4M | 143.55M | 197.59M | 214.86M | 143.78M | 140.67M | 132.75M |
R&D % of Revenue | 552.25% | 662.97% | 1301.15% | 326.28% | 27.39% | 185.56% | 1356.21% | 530.19% | 873.85% | - |
Other Operating Expenses | 600K | -598K | 140K | -124.44M | -11.43M | -5.99M | -2.86M | -1.38M | -3.77M | 122K |
Operating Income | -71.96M▲ 0% | -88.23M▼ 22.6% | -121.14M▼ 37.3% | -125.43M▼ 3.5% | 310.62M▲ 347.7% | -143.16M▼ 146.1% | -282.87M▼ 97.6% | -184.29M▲ 34.8% | -187.83M▼ 1.9% | -191.33M▲ 0% |
Operating Margin % | -549% | -781.92% | -1663.78% | -334.34% | 59.28% | -134.44% | -1785.46% | -679.58% | -1166.77% | -1057.48% |
Operating Income Growth % | -0.02% | -22.62% | -37.3% | -3.54% | 347.65% | -146.09% | -97.59% | 34.85% | -1.92% | - |
EBITDA | -64.41M | -81.33M | -114.47M | -114.78M | 317.92M | -134.62M | -270.97M | -171.65M | -173.07M | -178.14M |
EBITDA Margin % | -491.45% | -720.77% | -1572.19% | -305.96% | 60.67% | -126.43% | -1710.35% | -632.96% | -1075.09% | -984.59% |
EBITDA Growth % | 2.19% | -26.26% | -40.75% | -0.27% | 376.98% | -142.34% | -101.28% | 36.65% | -0.82% | -15.04% |
D&A (Non-Cash Add-back) | 7.54M | 6.9M | 6.67M | 10.65M | 7.3M | 8.54M | 11.9M | 12.64M | 14.76M | 13.19M |
EBIT | -77.23M | -80.91M | -120.39M | -137.62M | 311.7M | -116.56M | -265M | -173.39M | -131.35M | -168.06M |
Net Interest Income | -2.36M | 569K | -263K | -2.89M | -7.31M | -11.1M | -22M | -42.33M | -45.03M | -42.85M |
Interest Income | 117K | 2.73M | 3.55M | 938K | 162K | 609K | 19.56M | 21.41M | 16.97M | 18.07M |
Interest Expense | 2.48M | 2.16M | 3.81M | 3.83M | 7.47M | 11.7M | 41.56M | 63.74M | 61.99M | 60.92M |
Other Income/Expense | -8.12M | 5.16M | -3.06M | -16.02M | 22.19M | 14.9M | -23.69M | -52.83M | -5.51M | -11.92M |
Pretax Income | -80.59M▲ 0% | -83.07M▼ 3.1% | -124.2M▼ 49.5% | -141.44M▼ 13.9% | 332.81M▲ 335.3% | -128.26M▼ 138.5% | -306.56M▼ 139.0% | -237.13M▲ 22.6% | -193.34M▲ 18.5% | -203.25M▲ 0% |
Pretax Margin % | -614.85% | -736.2% | -1705.82% | -377.04% | 63.51% | -120.45% | -1934.97% | -874.39% | -1201.02% | -1123.34% |
Income Tax | -199K | 231K | 0 | -16.42M | 3.22M | -1.47M | 1.92M | 2.43M | 5.63M | 5.62M |
Effective Tax Rate % | 0.25% | -0.28% | 0% | 11.61% | 0.97% | 1.15% | -0.63% | -1.02% | -2.91% | -2.77% |
Net Income | -80.39M▲ 0% | -83.3M▼ 3.6% | -124.2M▼ 49.1% | -125.02M▼ 0.7% | 329.59M▲ 363.6% | -126.79M▼ 138.5% | -308.48M▼ 143.3% | -239.56M▲ 22.3% | -198.97M▲ 16.9% | -208.87M▲ 0% |
Net Margin % | -613.33% | -738.25% | -1705.82% | -333.27% | 62.9% | -119.07% | -1947.09% | -883.35% | -1236% | -1154.42% |
Net Income Growth % | -9.56% | -3.63% | -49.09% | -0.66% | 363.62% | -138.47% | -143.3% | 22.34% | 16.94% | 4% |
Net Income (Continuing) | -79.26M | -83.3M | -124.2M | -125.02M | 329.59M | -126.79M | -308.48M | -239.56M | -198.97M | -208.87M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.98▲ 0% | -2.34▲ 21.5% | -3.20▼ 36.8% | -2.81▲ 12.2% | 7.04▲ 350.5% | -2.71▼ 138.5% | -6.47▼ 138.7% | -4.92▲ 24.0% | -3.46▲ 29.7% | -3.33▲ 0% |
EPS Growth % | -1.71% | 21.48% | -36.75% | 12.19% | 350.53% | -138.49% | -138.75% | 23.96% | 29.67% | 20.05% |
EPS (Basic) | -2.98 | -2.34 | -3.20 | -2.81 | 7.17 | -2.71 | -6.47 | -4.92 | -3.46 | - |
Diluted Shares Outstanding | 26.98M | 35.64M | 40M | 44.47M | 46.84M | 46.74M | 47.67M | 48.65M | 57.5M | 62.74M |
Basic Shares Outstanding | 26.98M | 35.64M | 40M | 44.47M | 45.99M | 46.74M | 47.67M | 48.65M | 57.5M | 62.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
QURE Balance Sheet
uniQure N.V. (QURE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 162.78M | 236.58M | 384.21M | 258.91M | 628.24M | 476.77M | 651.85M | 390.29M | 655.99M | 615.74M |
Cash & Short-Term Investments | 159.37M | 234.9M | 377.79M | 244.93M | 556.26M | 352.84M | 617.89M | 367.52M | 622.54M | 586.55M |
Cash Only | 159.37M | 234.9M | 377.79M | 244.93M | 556.26M | 228.01M | 241.36M | 158.93M | 80.24M | 139.99M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 124.83M | 376.53M | 208.59M | 542.3M | 446.56M |
Accounts Receivable | 1.59M | 233K | 947K | 6.62M | 58.77M | 102.38M | 4.19M | 5.88M | 12.94M | 12.61M |
Days Sales Outstanding | 44.17 | 7.54 | 47.47 | 64.39 | 40.94 | 350.92 | 96.6 | 79.15 | 293.37 | 176.68 |
Inventory | 1.14M | 1.12M | 0 | 0 | 0 | 6.92M | 12.02M | 0 | 0 | 0 |
Days Inventory Outstanding | 6.17 | 5.58 | - | - | - | 755.99 | 322.04 | - | - | - |
Other Current Assets | 687K | 329K | -3.97M | 3.02M | 2.67M | 2.81M | 2.65M | 7.61M | 20.51M | 16.59M |
Total Non-Current Assets | 46.09M | 37.33M | 64.42M | 81.48M | 180.94M | 228.19M | 179.84M | 166.25M | 168.92M | 162.96M |
Property, Plant & Equipment | 34.28M | 29.18M | 55.57M | 58.41M | 69.08M | 83.26M | 75.34M | 34.07M | 26.32M | 24.27M |
Fixed Asset Turnover | 0.38x | 0.39x | 0.13x | 0.64x | 7.59x | 1.28x | 0.21x | 0.80x | 0.61x | 0.66x |
Goodwill | 530K | 506K | 496K | 542K | 27.63M | 25.58M | 26.38M | 22.41M | 25.36M | 24.81M |
Intangible Assets | 8.8M | 5.2M | 5.43M | 3.36M | 62.69M | 58.78M | 60.48M | 71.04M | 72.79M | 69.99M |
Long-Term Investments | 2.48M | 2.44M | 2.93M | 2.75M | 0 | 39.98M | 2.18M | 27.46M | 30.24M | 120.12M |
Other Non-Current Assets | 2.48M | 2.44M | 2.93M | 0 | 5.9M | 6.06M | 3.18M | 1.4M | 5.56M | 5.54M |
Total Assets | 208.88M▲ 0% | 273.91M▲ 31.1% | 448.63M▲ 63.8% | 340.39M▼ 24.1% | 809.18M▲ 137.7% | 704.96M▼ 12.9% | 831.69M▲ 18.0% | 556.54M▼ 33.1% | 824.91M▲ 48.2% | 778.71M▲ 0% |
Asset Turnover | 0.06x | 0.04x | 0.02x | 0.11x | 0.65x | 0.15x | 0.02x | 0.05x | 0.02x | 0.02x |
Asset Growth % | 9.78% | 31.13% | 63.79% | -24.13% | 137.72% | -12.88% | 17.98% | -33.08% | 48.22% | 94.44% |
Total Current Liabilities | 19.29M | 19.97M | 31.63M | 27.33M | 36.76M | 75.92M | 73.67M | 40.05M | 62.92M | 59.2M |
Accounts Payable | 2.91M | 3.79M | 5.68M | 3.77M | 2.5M | 10.98M | 6.59M | 7.23M | 5.17M | 4.4M |
Days Payables Outstanding | 15.75 | 18.94 | - | 11.25 | 36.56 | 1.2K | 176.39 | 143.93 | 1.12K | 416.22 |
Short-Term Debt | 1.05M | 0 | 0 | 5.52M | 5.77M | 8.38M | 0 | 0 | 3.86M | 2.99M |
Deferred Revenue (Current) | 4.61M | 7.63M | 7.63M | 2.08M | 13.01M | 11.12M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2.67M | 856K | 0 | 8.27M | 2.87M | 28.23M | 45.91M | 19.12M | 53.89M | 51.81M |
Current Ratio | 8.44x | 11.85x | 12.15x | 9.47x | 17.09x | 6.28x | 8.85x | 9.74x | 10.43x | 10.40x |
Quick Ratio | 8.38x | 11.79x | 12.15x | 9.47x | 17.09x | 6.19x | 8.68x | 9.74x | 10.43x | 10.40x |
Cash Conversion Cycle | 34.59 | -5.83 | - | - | - | -92.36 | 242.25 | - | - | -239.54 |
Total Non-Current Liabilities | 99.64M | 74.33M | 93.94M | 69.16M | 176.64M | 153.04M | 550.34M | 523.24M | 563.09M | 570.17M |
Long-Term Debt | 19.74M | 35.47M | 36.06M | 35.62M | 100.96M | 102.79M | 101.75M | 51.32M | 522.9M | 60.33M |
Capital Lease Obligations | 0 | 0 | 31.13M | 30.4M | 28.99M | 31.72M | 28.32M | 11.14M | 9.83M | 31.14M |
Deferred Tax Liabilities | 10.41M | 9.56M | 0 | 0 | 12.91M | 8.26M | 7.54M | 7.04M | 7.97M | 31.68M |
Other Non-Current Liabilities | 13.91M | 10M | 3.61M | 3.14M | 33.78M | 10.27M | 412.74M | 453.73M | 22.39M | 502.04M |
Total Liabilities | 118.93M | 94.3M | 125.57M | 96.49M | 213.4M | 228.96M | 624.02M | 563.29M | 626.01M | 629.36M |
Total Debt | 20.18M | 35.47M | 73.06M | 71.54M | 135.72M | 142.89M | 138.41M | 66.06M | 536.59M | 63.32M |
Net Debt | -139.2M | -199.43M | -304.73M | -173.39M | -420.53M | -85.12M | -102.95M | -92.87M | 456.35M | -76.67M |
Debt / Equity | 0.22x | 0.20x | 0.23x | 0.29x | 0.23x | 0.30x | 0.67x | - | 2.70x | 0.42x |
Debt / EBITDA | - | - | - | - | 0.43x | - | - | - | - | -0.36x |
Net Debt / EBITDA | - | - | - | - | -1.32x | - | - | - | - | 0.43x |
Interest Coverage | -31.20x | -37.46x | -31.60x | -35.98x | 41.70x | -9.96x | -6.38x | -2.72x | -2.12x | -2.76x |
Total Equity | 89.94M▲ 0% | 179.61M▲ 99.7% | 323.06M▲ 79.9% | 243.91M▼ 24.5% | 595.78M▲ 144.3% | 476.01M▼ 20.1% | 207.67M▼ 56.4% | -6.75M▼ 103.3% | 198.9M▲ 3045.8% | 149.34M▲ 0% |
Equity Growth % | 41.35% | 99.68% | 79.87% | -24.5% | 144.27% | -20.1% | -56.37% | -103.25% | 3045.81% | 3594.81% |
Book Value per Share | 3.33 | 5.04 | 8.08 | 5.49 | 12.72 | 10.19 | 4.36 | -0.14 | 3.46 | 2.38 |
Total Shareholders' Equity | 89.94M | 179.61M | 323.06M | 243.91M | 595.78M | 476.01M | 207.67M | -6.75M | 198.9M | 149.34M |
Common Stock | 1.95M | 2.3M | 2.65M | 2.71M | 2.8M | 2.84M | 2.88M | 2.94M | 3.69M | 3.73M |
Retained Earnings | -467.12M | -535.51M | -659.71M | -784.73M | -455.14M | -581.93M | -890.41M | -1.13B | -1.33B | -1.38B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 39.08M | -7.26M | -6.69M | 9.91M | -28.86M | -58.29M | -53.55M | -52.8M | -58.22M | -59.88M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QURE Cash Flow Statement
uniQure N.V. (QURE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -64.27M | -76.04M | -98.68M | -134.83M | 287.96M | -145.06M | -145.93M | -182.73M | -177.96M | -172.11M |
Operating CF Margin % | -490.35% | -673.85% | -1355.36% | -359.41% | 54.95% | -136.23% | -921.09% | -673.8% | -1105.5% | - |
Operating CF Growth % | 10.97% | -18.31% | -29.78% | -36.63% | 313.58% | -150.38% | -0.6% | -25.22% | 2.61% | -0.28% |
Net Income | -80.39M | -83.3M | -124.2M | -125.02M | 329.59M | -126.79M | -308.48M | -239.56M | -198.97M | -208.87M |
Depreciation & Amortization | 8.31M | 12.41M | 6.67M | 10.65M | 7.3M | 8.54M | 11.9M | 12.64M | 14.76M | 5.93M |
Stock-Based Compensation | 10.13M | 10.71M | 17.53M | 21.83M | 25.64M | 34.2M | 35.09M | 22.26M | 17.68M | 18.36M |
Deferred Taxes | 209K | 231K | 0 | -16.42M | 3.21M | -1.47M | 1.92M | 2.43M | 1.59M | 1.55M |
Other Non-Cash Items | 10.12M | -9.89M | 3.42M | -19.39M | -27.29M | -16.16M | 32.51M | 23.44M | -6.23M | 4.32M |
Working Capital Changes | -12.65M | -6.2M | -2.11M | -6.47M | -50.48M | -43.38M | 81.12M | -3.94M | -6.79M | 6.61M |
Change in Receivables | 9.71M | 1.58M | -4.77M | -6.97M | -58.96M | -49.08M | -1.32M | -2.24M | -8.6M | -1.84M |
Change in Inventory | 382K | -382K | 4.77M | 0 | 0 | -6.92M | -6.74M | 2.42M | 0 | 0 |
Change in Payables | -1.67M | 1.06M | 1.65M | -2.7M | -727K | 9.24M | -4.17M | 1.52M | -2.67M | -1.13M |
Cash from Investing | -6.15M | -4.25M | -6.65M | -9.48M | -67.39M | -182.73M | -205.69M | 162.97M | -321.62M | -258.75M |
Capital Expenditures | -5.58M | -4.25M | -6.65M | -7.27M | -17.44M | -17.69M | -7.15M | -11.69M | -439K | -14K |
CapEx % of Revenue | 42.6% | 37.62% | 91.29% | 19.38% | 3.33% | 16.61% | 45.16% | 43.1% | 2.73% | 0.08% |
Acquisitions | 0 | 0 | 0 | 0 | -49.95M | -1.9M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -567K | -1.86M | 0 | -2.21M | 0 | 0 | 0 | 0 | 0 | -357.44M |
Cash from Financing | 90.07M | 157.96M | 248.82M | 7.44M | 94.86M | 1.45M | 362.72M | -59.49M | 415.4M | 329.26M |
Debt Issued (Net) | 0 | 14.78M | 0 | 0 | 62.49M | 0 | 370.06M | -53.05M | 0 | 0 |
Equity Issued (Net) | 85.29M | 138.36M | 242.72M | 7.44M | 33.7M | 1.45M | 308K | 2.12M | 391.9M | -80.12M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 4.78M | 4.83M | 6.1M | 0 | -1.33M | 0 | -7.65M | -8.56M | 23.5M | 409.38M |
Net Change in Cash | 26.88M▲ 0% | 75.49M▲ 180.9% | 143.38M▲ 89.9% | -133.05M▼ 192.8% | 311.67M▲ 334.3% | -328.18M▼ 205.3% | 13.37M▲ 104.1% | -84.22M▼ 729.8% | -78.69M▲ 6.6% | -77.19M▲ 0% |
Free Cash Flow | -69.85M▲ 0% | -80.28M▼ 14.9% | -105.33M▼ 31.2% | -144.31M▼ 37.0% | 270.52M▲ 287.5% | -162.75M▼ 160.2% | -153.08M▲ 5.9% | -186.1M▼ 21.6% | -177.96M▲ 4.4% | -172.12M▲ 0% |
FCF Margin % | -532.94% | -711.47% | -1446.66% | -384.69% | 51.63% | -152.84% | -966.25% | -686.22% | -1105.5% | -951.31% |
FCF Growth % | 21.83% | -14.93% | -31.2% | -37.01% | 287.46% | -160.16% | 5.94% | -21.57% | 4.37% | 2.05% |
FCF per Share | -2.59 | -2.25 | -2.63 | -3.25 | 5.78 | -3.48 | -3.21 | -3.83 | -3.09 | -2.74 |
FCF Conversion (FCF/Net Income) | 0.80x | 0.91x | 0.79x | 1.08x | 0.87x | 1.14x | 0.47x | 0.76x | 0.89x | 0.82x |
Interest Paid | 0 | 0 | 0 | 4.13M | 6.54M | 9.25M | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
QURE Key Ratios
uniQure N.V. (QURE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -104.69% | -61.81% | -49.42% | -44.1% | 78.5% | -23.66% | -90.24% | -238.46% | -207.1% | -145.81% |
Return on Invested Capital (ROIC) | - | - | - | -211.77% | 189.59% | -37.93% | -85.61% | -5422.54% | -50.71% | -244.58% |
Gross Margin | -414.3% | -547.47% | 100% | -226.28% | 95.23% | 96.86% | 13.98% | 32.42% | 89.53% | 74.14% |
Net Margin | -613.33% | -738.25% | -1705.82% | -333.27% | 62.9% | -119.07% | -1947.09% | -883.35% | -1236% | -1154.42% |
Debt / Equity | 0.22x | 0.20x | 0.23x | 0.29x | 0.23x | 0.30x | 0.67x | - | 2.70x | 0.42x |
Interest Coverage | -31.20x | -37.46x | -31.60x | -35.98x | 41.70x | -9.96x | -6.38x | -2.72x | -2.12x | -2.76x |
FCF Conversion | 0.80x | 0.91x | 0.79x | 1.08x | 0.87x | 1.14x | 0.47x | 0.76x | 0.89x | 0.82x |
Revenue Growth | -47.78% | -13.91% | -35.48% | 415.23% | 1296.82% | -79.68% | -85.12% | 71.17% | -40.64% | -10.44% |
Related:QURE Dividend History·QURE Revenue History·QURE Price History·QURE P/E History·QURE Financial Ratios·QURE Institutional Holders
QURE SEC Filings & Documents
uniQure N.V. (QURE) SEC filings — annual & quarterly reports (10-K, 10-Q)
QURE Frequently Asked Questions
uniQure N.V. (QURE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
uniQure N.V. (QURE) reported $18.1M in revenue for fiscal year 2025.
uniQure N.V. (QURE) saw revenue decline by 40.6% over the past year.
uniQure N.V. (QURE) reported a net loss of $208.9M for fiscal year 2025.
Dividend & Returns
uniQure N.V. (QURE) has a return on equity (ROE) of -207.1%. Negative ROE indicates the company is unprofitable.
uniQure N.V. (QURE) had negative free cash flow of $172.1M in fiscal year 2025, likely due to heavy capital investments.